{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:58:51Z","timestamp":1774529931669,"version":"3.50.1"},"reference-count":139,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.nephro.2015.06.002","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T05:19:10Z","timestamp":1443590350000},"page":"507-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prise en charge de l\u2019infection par les virus des h\u00e9patites\u00a0B ou\u00a0C chez l\u2019insuffisant r\u00e9nal chronique"],"prefix":"10.1684","volume":"11","author":[{"given":"Ana\u00efs","family":"Vallet-Pichard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2015.06.002_bib0700","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0272-6386(95)90617-7","article-title":"Hepatitis\u00a0C virus: the nephrologist's view","volume":"25","author":"Roth","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.06.002_bib0705","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ki.1997.139","article-title":"Hepatitis\u00a0C virus infection in dialysis and renal transplantation","volume":"51","author":"Pereira","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.06.002_bib0710","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.1840170103","article-title":"Prevalence of hepatitis\u00a0C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays","volume":"17","author":"Chan","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.nephro.2015.06.002_bib0715","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1523-1755.1998.00823.x","article-title":"The Universitaires Cliniques St-Luc (UCL) Collaborative Group Universal precautions prevent hepatitis\u00a0C virus transmission: a 54\u00a0month follow-up of the Belgian Multicenter Study","volume":"53","author":"Jadoul","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.06.002_bib0720","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3748\/wjg.14.2288","article-title":"Occult hepatitis\u00a0C virus infection is more common than hepatitis\u00a0B infection in maintenance hemodialysis patients","volume":"14","author":"Jain","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0725","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.transproceed.2008.03.031","article-title":"Relationship of hepatitis\u00a0B or\u00a0C virus prevalences, risk factors, and outcomes in renal transplant recipients: analysis of German data","volume":"40","author":"Kliem","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2015.06.002_bib0730","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/j.1572-0241.2001.03701.x","article-title":"Acute hepatitis\u00a0C among Japanese hemodialysis patients: a prospective 9-year study","volume":"96","author":"Furusyo","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0735","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa0706992","article-title":"Hepatitis\u00a0E virus and chronic hepatitis in organ-transplant recipients","volume":"358","author":"Kamar","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib0740","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-153-2-201007200-00257","article-title":"Brief communication: case reports of ribavirin treatment for chronic hepatitis\u00a0E","volume":"153","author":"Mallet","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib0745","first-page":"131","article-title":"GBV-C\/HGV infection in end-stage renal disease","volume":"12","author":"Fabrizi","year":"1999","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0750","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00007890-199902270-00012","article-title":"Long-term impact of superinfection by hepatitis\u00a0G virus in hepatitis\u00a0C virus-positive renal transplant patients","volume":"67","author":"Rostaing","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0755","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis\u00a0B and\u00a0C virus on kidney transplantation outcome","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.nephro.2015.06.002_bib0760","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1034\/j.1399-0012.2002.1o034.x","article-title":"Impact of hepatitis\u00a0B and C on graft loss and mortality of patients after kidney transplantation","volume":"16","author":"Breitenfeldt","year":"2002","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib0765","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00007890-199803150-00011","article-title":"Harmful long-term impact of hepatitis\u00a0C virus infection in kidney transplant recipients","volume":"65","author":"Legendre","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0770","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis\u00a0C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand","volume":"90","author":"Scott","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0775","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(81)92679-9","article-title":"Randomised placebo-controlled trial of hepatitis\u00a0B surface antigen vaccine in french haemodialysis units: II","volume":"1","author":"Crosnier","year":"1981","journal-title":"Haemodialysis patients. Lancet"},{"key":"10.1016\/j.nephro.2015.06.002_bib0780","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00007890-199212000-00027","article-title":"Absence of hepatitis delta virus infection in chronic hemodialysis and kidney transplant patients in France","volume":"54","author":"Pol","year":"1992","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0785","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/00007890-199710150-00022","article-title":"Nephrotic syndrome after liver transplantation in a patient with hepatitis\u00a0C virus-associated glomerulonephritis","volume":"64","author":"Pascual","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0790","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/00007890-199706150-00017","article-title":"Membranous glomerulonephritis associated with hepatitis\u00a0C virus infection in renal transplant patients","volume":"63","author":"Morales","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0795","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-150-1-200901060-00007","article-title":"Nonhospital Health care-associated hepatitis\u00a0B and C virus transmission: United States, 1998\u20132008","volume":"150","author":"Thompson","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib0800","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jmv.1890430417","article-title":"Hepatitis\u00a0C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment","volume":"43","author":"Allander","year":"1994","journal-title":"J Med Virol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0805","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis\u00a0C in chronic kidney disease","volume":"109","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2008","journal-title":"Kidney Int suppl"},{"key":"10.1016\/j.nephro.2015.06.002_bib0810","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis\u00a0C infection","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0815","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/ndt\/13.7.1804","article-title":"Absence of HCV viraemia in anti-HCV-negative haemodialysis patients","volume":"13","author":"Dalekos","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib0820","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jcv.2005.05.007","article-title":"HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis\u00a0C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece","volume":"34","author":"Rigopoulou","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0825","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/ndt\/16.5.1017","article-title":"The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study","volume":"16","author":"Degos","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib0830","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0016-5085(95)90088-8","article-title":"The changing relative prevalence of hepatitis\u00a0C virus genotypes: evidence in hemodialyzed patients and kidney recipients","volume":"108","author":"Pol","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nephro.2015.06.002_bib0835","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ndt\/16.8.1669","article-title":"Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients","volume":"16","author":"Espinosa","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib0840","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/00007890-200004150-00045","article-title":"Histopathological features of hepatitis\u00a0C in renal transplant candidates","volume":"69","author":"Martin","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0845","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2036.2004.02290.x","article-title":"Meta-analysis: Effect of hepatitis\u00a0C virus infection on mortality in dialysis","volume":"20","author":"Fabrizi","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.nephro.2015.06.002_bib0850","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/gast.2002.36610","article-title":"Long-term impact of renal transplantation on liver fibrosis during hepatitis\u00a0C virus infection","volume":"123","author":"Alric","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nephro.2015.06.002_bib0855","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1600-6143.2005.00918.x","article-title":"Natural history of hepatitis\u00a0C virus-related liver fibrosis after renal transplantation","volume":"5","author":"Kamar","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib0860","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/TP.0b013e3181837761","article-title":"Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation","volume":"86","author":"Hoffmann","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0865","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.21990","article-title":"Survival and recurrence of hepatitis\u00a0C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis\u00a0C virus","volume":"47","author":"Duclos-Vall\u00e9e","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.nephro.2015.06.002_bib0870","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00007890-199510000-00007","article-title":"The impact of pretransplantation hepatitis\u00a0C infection on the outcome of renal transplantation","volume":"60","author":"Pereira","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0875","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/00007890-199606270-00019","article-title":"Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis","volume":"61","author":"Pol","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0880","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00007890-199701150-00029","article-title":"Hepatitis\u00a0C virus-related fibrosing cholestatic hepatitis after renal transplantation","volume":"63","author":"Zylberberg","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib0885","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1056\/NEJM199403173301104","article-title":"Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis\u00a0C virus","volume":"330","author":"Misiani","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib0890","first-page":"451","article-title":"Frequency and role of hepatitis-C virus and type\u00a0II cryoglobulinemia in membranoproliferative glomerulonephritis","volume":"52","author":"Prakash","year":"2004","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.nephro.2015.06.002_bib0895","first-page":"ii41","article-title":"Renal transplantation in patients with hepatitis\u00a0C virus antibody. A long national experience","volume":"3","author":"Morales","year":"2010","journal-title":"NDT plus"},{"key":"10.1016\/j.nephro.2015.06.002_bib0900","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/BOR.0b013e3282f1330c","article-title":"Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis","volume":"20","author":"Saadoun","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0905","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.20958","article-title":"Pegylated interferon alfa-2b and ribavirin treatment in patients with hepatitis\u00a0C virus-related systemic vasculitis","volume":"52","author":"Cacoub","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nephro.2015.06.002_bib0910","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis\u00a0C virus-associated mixed cryoglobulinemia vasculitis: a long term follow up study","volume":"54","author":"Saadoun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nephro.2015.06.002_bib0915","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2007.081653","article-title":"Rituximab combined with peg-interferon-ribavirin in refractory hepatitis\u00a0C virus-associated cryoglobulinaemia vasculitis","volume":"67","author":"Saadoun","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nephro.2015.06.002_bib0920","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2011.07.005","article-title":"Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature","volume":"11","author":"Ferri","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nephro.2015.06.002_bib0925","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/art.24703","article-title":"Efficacy and tolerability of rituximab with or without pegylated interferon alfa-2b plus ribavirin in severe hepatitis\u00a0C virus-related systemic vasculitis: a long-term followup study of thirty-two patients","volume":"60","author":"Terrier","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nephro.2015.06.002_bib0930","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","article-title":"Rituximab plus Peg-interferon-alfa\/ribavirin in hepatitis\u00a0C virus-related mixed cryoglobulinemia","volume":"116","author":"Saadoun","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2015.06.002_bib0935","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-133-8-200010170-00009","article-title":"Prevalence of type\u00a02\u00a0diabetes mellitus among persons with hepatitis\u00a0C virus infection in the United States","volume":"133","author":"Mehta","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib0940","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20092","article-title":"New onset diabetes mellitus after liver transplantation: the critical role of hepatitis\u00a0C infection","volume":"10","author":"Khalili","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.nephro.2015.06.002_bib0945","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/039139880803100801","article-title":"Hepatitis\u00a0C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis","volume":"31","author":"Fabrizi","year":"2008","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.nephro.2015.06.002_bib0950","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1016\/j.transproceed.2009.07.054","article-title":"Frequency and risk factors for posttransplant diabetes mellitus in Iranian renal transplant patients","volume":"41","author":"Ossareh","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2015.06.002_bib0955","doi-asserted-by":"crossref","first-page":"E170","DOI":"10.1111\/j.1399-0012.2010.01247.x","article-title":"Risk factors and consequences of post-transplant diabetes mellitus","volume":"24","author":"Demirci","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib0960","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000325778","article-title":"New-onset diabetes and nephropathy after renal transplantation","volume":"170","author":"Guitard","year":"2011","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0965","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5414\/CNP71423","article-title":"Geographical prevalence, risk factors and impact of hepatitis\u00a0B and C after renal transplantation","volume":"71","author":"Kliem","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0970","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2362.2000.00608.x","article-title":"Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4\u00a0months therapy with interferon-alpha","volume":"30","author":"Konrad","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.nephro.2015.06.002_bib0975","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1111\/j.1600-6143.2009.02843.x","article-title":"Impaired insulin sensitivity as an underlying mechanism linking hepatitis\u00a0C and posttransplant diabetes mellitus in kidney recipients","volume":"9","author":"Baid-Agrawal","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib0980","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0168-8278(00)80065-3","article-title":"Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis\u00a0C, alcohol, or cholestatic disease","volume":"32","author":"Zein","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.nephro.2015.06.002_bib0985","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/j.1600-6143.2005.01040.x","article-title":"Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib0990","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/ndt\/16.1.193","article-title":"Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis\u00a0C: results of a pilot study","volume":"16","author":"Tan","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib0995","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/039139880803100404","article-title":"Treatment of dialysis patients with chronic hepatitis\u00a0C using pegylated interferon and low-dose ribavirin","volume":"31","author":"Carriero","year":"2008","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.nephro.2015.06.002_bib1000","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2010.10.018","article-title":"Low-dose peginterf\u00e9ron alfa-2a (40KD) is safe and produces a SVR in patients with chronic hepatitis\u00a0C and end-stage renal disease","volume":"9","author":"Peck-Radosavljevic","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1005","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1097\/01.tp.0000183399.85804.02","article-title":"Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis\u00a0C virus","volume":"80","author":"Varaut","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study","volume":"55","author":"Foucher","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.nephro.2015.06.002_bib1015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1432-2277.2009.00834.x","article-title":"Comparison of liver stiffness, fibrotest and liver biospy for assessment of liver fibrosis in kidney transplant patients with chronic viral hepatitis\u00a0C","volume":"22","author":"Alric","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.nephro.2015.06.002_bib1020","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.transproceed.2009.06.103","article-title":"Correlation between fibroscan, liver biopsy, and clinical liver function in patients with hepatitis\u00a0C virus infection after renal transplantation","volume":"41","author":"Munoz","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2015.06.002_bib1025","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.humpath.2006.07.007","article-title":"Direct and indirect evidence for the reversibility of cirrhosis","volume":"37","author":"Serpaggi","year":"2006","journal-title":"Hum Pathol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.humpath.2003.08.012","article-title":"Reversibility of hepatitis\u00a0C virus-related cirrhosis","volume":"35","author":"Pol","year":"2004","journal-title":"Hum Pathol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"The relationship of regression of cirrhosis to outcome in chronic hepatitis\u00a0C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib1040","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1086\/517339","article-title":"High rate of hepatitis\u00a0C virus clearance in hemodialysis patients after interferon-alpha therapy","volume":"176","author":"Izopet","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nephro.2015.06.002_bib1045","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/ki.1994.197","article-title":"Interferon treatment for chronic hepatitis\u00a0C virus infection in uremic patients","volume":"45","author":"Koenig","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.06.002_bib1050","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.1995.198","article-title":"Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients","volume":"47","author":"Pol","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.06.002_bib1055","first-page":"1170","article-title":"Efficacy of interferon for chronic hepatitis\u00a0C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation","volume":"96","author":"Casanovas-Taltavull","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1060","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1097\/01.ASN.0000079613.81511.3C","article-title":"Evidence that clearance of hepatitis\u00a0C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation","volume":"14","author":"Kamar","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1065","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1432-2277.2009.01025.x","article-title":"No evidence of occult hepatitis\u00a0C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients","volume":"23","author":"Nicot","year":"2010","journal-title":"Transplant Int"},{"key":"10.1016\/j.nephro.2015.06.002_bib1070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1365-2893.2001.00268.x","article-title":"Interferon therapy in haemodialysis patients with acute hepatitis\u00a0C virus infection and factors that predict response to treatment","volume":"8","author":"Gursoy","year":"2001","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.nephro.2015.06.002_bib1075","first-page":"293","article-title":"Treatment of acute hepatitis\u00a0C virus infection with alpha interferon in patients on hemodialysis","volume":"16","author":"Al-Harbi","year":"2005","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib1080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/655682","article-title":"Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis\u00a0C","volume":"51","author":"Liu","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2015.06.002_bib1085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00007890-199409150-00018","article-title":"Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis\u00a0C viral infection in renal transplant recipients. A pilot study","volume":"58","author":"Thervet","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1090","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0041-1345(96)00100-5","article-title":"Treatment of hepatitis\u00a0C virus infection with ribavirin in kidney transplant patients","volume":"29","author":"Garnier","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2015.06.002_bib1095","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0272-6386(03)00422-0","article-title":"Long-term ribavirin therapy in hepatitis\u00a0C virus-positive renal transplant patients: effects on renal function and liver histology","volume":"42","author":"Kamar","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.06.002_bib1100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.TP.0000128911.87538.AA","article-title":"Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis\u00a0C","volume":"78","author":"Fontaine","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1105","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1097\/01.TP.0000131151.07818.D7","article-title":"Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis\u00a0C in renal transplant recipients","volume":"77","author":"Shu","year":"2004","journal-title":"Transplantation"},{"issue":"suppl\u00a03","key":"10.1016\/j.nephro.2015.06.002_bib1110","first-page":"S52","article-title":"KDIGO Clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib1115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/00007890-200003150-00055","article-title":"Changes in hepatitis\u00a0C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil","volume":"69","author":"Rostaing","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0016-5085(88)90623-3","article-title":"Hepatitis\u00a0B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90\u00a0patients","volume":"94","author":"Degos","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nephro.2015.06.002_bib1125","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1525-139X.2008.00437.x","article-title":"Hepatitis\u00a0B virus infection and the dialysis patient","volume":"21","author":"Fabrizi","year":"2008","journal-title":"Semin Dial"},{"key":"10.1016\/j.nephro.2015.06.002_bib1130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJM197701272960404","article-title":"Long-term effect of HBs antigenemia on patient survival after renal transplantation","volume":"296","author":"Pirson","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib1135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00007890-199607270-00025","article-title":"The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis\u00a0B virus infection","volume":"62","author":"Fornairon","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1140","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/0016-5085(94)90557-6","article-title":"Fibrosing cholestatic hepatitis in a hepatitis\u00a0B surface antigen carrier after renal transplantation","volume":"107","author":"Chen","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nephro.2015.06.002_bib1145","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM198408233110803","article-title":"Hepatitis\u00a0B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy","volume":"311","author":"Stevens","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib1150","first-page":"143","article-title":"Hepatitis\u00a0B vaccine: randomized trial of immunogenicity in hemodialysis patients","volume":"21","author":"Benhamou","year":"1984","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1155","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1001\/jama.1991.03460200059035","article-title":"Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis\u00a0B vaccination in Japanese medical personnel","volume":"265","author":"Nagafuchi","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.nephro.2015.06.002_bib1160","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(94)92829-0","article-title":"Randomised placebo-controlled trial of recombinant interleukin-2\u00a0in chronic uraemic patients who are non-responders to hepatitis\u00a0B vaccine","volume":"344","author":"Jungers","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2015.06.002_bib1165","first-page":"1369","article-title":"Effects of interleukin-2\u00a0on hepatitis\u00a0B vaccination in uraemic patients","volume":"344","author":"Pol","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2015.06.002_bib1170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V100.2.391","article-title":"Lamivudine therapy for prevention of immunosuppressive-induced hepatitis\u00a0B virus reactivation in hepatitis\u00a0B surface antigen carriers","volume":"100","author":"Shibolet","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2015.06.002_bib1175","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00007890-200102150-00008","article-title":"Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence","volume":"71","author":"Han","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1180","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis\u00a0B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nephro.2015.06.002_bib1185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practical guidelines","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis\u00a0B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.nephro.2015.06.002_bib1195","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis\u00a0B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib1200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2006-939752","article-title":"Hepatitis\u00a0B virus-related cirrhosis: natural history and treatment","volume":"26","author":"Chu","year":"2006","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.nephro.2015.06.002_bib1205","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1038\/sj.onc.1209559","article-title":"Hepatitis\u00a0B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis","volume":"25","author":"Kremsdorf","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.nephro.2015.06.002_bib1210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis\u00a0B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.nephro.2015.06.002_bib1215","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis\u00a0B","volume":"334","author":"Niederau","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib1220","first-page":"1353","article-title":"Adefovir dipivoxil therapy for lamivudine-resistant hepatitis\u00a0B in pre- and post-liver transplantation patients","volume":"38","author":"Schiff","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.nephro.2015.06.002_bib1225","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis\u00a0B for up to 5\u00a0years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nephro.2015.06.002_bib1230","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of Entecavir and lamivudine for HBe Ag-positive chronic hepatitis\u00a0B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib1235","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disiproxyl fumarate contre adefovir dipivoxil (ADV) for chronic hepatitis\u00a0B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib1240","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine contre lamivudine in patients with chronic hepatitis\u00a0B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib1245","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis\u00a0B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2015.06.002_bib1250","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a (40KD) (PEGASYS\u00ae) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis\u00a0B: results from a large, multinational study","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.06.002_bib1255","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/j.1572-0241.2006.00769.x","article-title":"Treatment alternatives for hepatitis\u00a0B cirrhosis: a cost-effectiveness analysis","volume":"101","author":"Kanwal","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1260","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1097\/00007890-199712150-00025","article-title":"Efficacy and safety of lamivudine on replication of recurrent hepatitis\u00a0B after cadaveric renal transplantation","volume":"64","author":"Rostaing","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1265","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1097\/00007890-200005270-00020","article-title":"HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients","volume":"69","author":"Fontaine","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1270","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/01.tp.0000178305.39231.a2","article-title":"Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency","volume":"80","author":"Fontaine","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1275","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/jlts.2003.50010","article-title":"Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency","volume":"9","author":"Tillmann","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.nephro.2015.06.002_bib1280","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/TP.0b013e3181806c8c","article-title":"Entecavir therapy for adefovir-resistant hepatitis\u00a0B virus infection in kidney and liver allograft recipients","volume":"86","author":"Kamar","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.06.002_bib1285","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000077065","article-title":"Hepatitis\u00a0B virus-associated nephropathy","volume":"24","author":"Bhimma","year":"2004","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1290","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0168-8278(02)80487-1","article-title":"Dosing guidelines for Adefovir Dipivoxil in the treatment of HBV infected patients with renal or hepatic impairment","volume":"36","author":"Knight","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1295","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","article-title":"Renal safety of adefovir dipivoxil in patients with chronic hepatitis\u00a0B: two double-blind, randomized, placebo-controlled studies","volume":"66","author":"Izzedine","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.06.002_bib1300","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0929-6646(08)60054-6","article-title":"Complete remission of nephrotic syndrome of hepatitis\u00a0B virus-associated membranous glomerulopathy after lamivudine monotherapy","volume":"106","author":"Chuang","year":"2007","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.nephro.2015.06.002_bib1305","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/039139880803100503","article-title":"Hepatitis\u00a0B virus infection in the dialysis population: current perspectives","volume":"31","author":"Fabrizi","year":"2008","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.nephro.2015.06.002_bib1310","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1081\/NCN-100002341","article-title":"Human renal organic anion transporter\u00a01 (hOAT1) and its role in the nephrotoxiciy of antiviral nucleotide analogues","volume":"20","author":"Cihlar","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.nephro.2015.06.002_bib1315","first-page":"708A","article-title":"High risk of renal impairement and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis\u00a0B","volume":"48","author":"Vigano","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.nephro.2015.06.002_bib1320","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S0168-8278(08)60075-6","article-title":"A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience","volume":"48","author":"Van B\u00f6mmel","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1325","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/S0168-8278(08)60696-0","article-title":"MDRD creatinine clearance is not altered in HIV-HBV co-inected patients with a normal renal function and treated with tenofovir (TDF)","volume":"48","author":"Lacombe","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1330","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1086\/368314","article-title":"Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus","volume":"36","author":"Karras","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2015.06.002_bib1335","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/01.qai.0000138983.45235.02","article-title":"Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study","volume":"37","author":"Jones","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.nephro.2015.06.002_bib1340","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1034\/j.1600-6143.2003.00050.x","article-title":"Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation","volume":"3","author":"Cr\u00e9put","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib1345","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.transproceed.2004.07.025","article-title":"Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis\u00a0C","volume":"36","author":"Mousa","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2015.06.002_bib1350","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.transproceed.2005.02.054","article-title":"Treatment of hepatitis\u00a0C virus with interferon in hemodialysis patients awaiting kidney transplant","volume":"37","author":"Rivera","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2015.06.002_bib1355","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/08860220701641579","article-title":"Treatment of hepatitis\u00a0C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy","volume":"29","author":"Sikole","year":"2007","journal-title":"Ren Fail"},{"key":"10.1016\/j.nephro.2015.06.002_bib1360","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ndt\/gfm724","article-title":"Pegylated interferon alfa-2a (40\u00a0kD) and ribavirin in haemodialysis patients with chronic hepatitis\u00a0C","volume":"23","author":"Van Leusen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.06.002_bib1365","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3748\/wjg.14.255","article-title":"Efficacy and safety of pegylated interferon alfa-2a in hemodialysis patients with chronic hepatitis\u00a0C","volume":"14","author":"Ayaz","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1370","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s15010-008-7134-z","article-title":"The response to pegylated interferon alfa 2a in haemodialysis patients with hepatitis\u00a0C virus infection","volume":"36","author":"Akhan","year":"2008","journal-title":"Infection"},{"key":"10.1016\/j.nephro.2015.06.002_bib1375","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00535-009-0016-z","article-title":"Treatment of hepatitis\u00a0C in hemodialysis patients using pegylated interferon alpha-2a in Turkey","volume":"44","author":"Kose","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1380","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/039139880903200309","article-title":"Long-term follow-up of sustained viral response after treatment of hepatitis\u00a0C with pegylated interferon alpha-2a in hemodialysis patients","volume":"32","author":"Dzekova","year":"2009","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.nephro.2015.06.002_bib1385","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11255-010-9756-1","article-title":"Pegylated interferon alfa-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience","volume":"43","author":"Alsaran","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.nephro.2015.06.002_bib1390","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2010.10.018","article-title":"Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis\u00a0C and end-stage renal disease","volume":"9","author":"Peck-Radosavljevic","year":"2011","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725515001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725515001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2015.06.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:21:16Z","timestamp":1741191676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725515001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":139,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1769725515001194"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2015.06.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge de l\u2019infection par les virus des h\u00e9patites\u00a0B ou\u00a0C chez l\u2019insuffisant r\u00e9nal chronique","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2015.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}